A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
2期
已完成
NCT05775289
| 适应症 | Non-small Cell Lung Cancer |
|---|
| 分期 | 2期 |
|---|
| 申办方 | Hoffmann-La Roche |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 182 人 |
|---|
| 干预（药物） | Tobemstomig, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin |
|---|
| 开始日期 | 2023年3月15日 |
|---|
| 完成日期 | 2024年6月20日 |
|---|
| 结果公布日 | 2025年11月19日 |
|---|
摘要
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based chemotherapy compared with pembrolizumab plus platinum-based chemotherapy in participants with previously untreated, locally advanced, unresectable (Stage IIIB/IIIC) or metastatic (Stage IV) non-small-cell lung cancer (NSCLC) who are not eligible to receive curative surgery and/or definitive chemoradiotherapy.
Progression-Free Survival (PFS)
Randomization to date of first documented disease progression or death (up to approximately 15 months) · Months
| Pembro + Chemotherapy | 7.13 Months |
|---|
| Tobe + Chemotherapy | 7.62 Months |
|---|
| p-value | 0.9705 |
|---|
| Hazard Ratio (HR) | 0.99 (95% CI 0.63–1.56) |
|---|
Objective Response Rate (ORR)
Up to approximately 15 months · Percent of participants
| Pembro + Chemotherapy | 46.2 Percent of participants |
|---|
| Tobe + Chemotherapy | 41.1 Percent of participants |
|---|
| p-value | 0.4056 |
|---|
| Odds Ratio (OR) | 0.77 (95% CI 0.42–1.43) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。